Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1693
This examiner grants 54% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19275384 | VERSATILE SYNTHETIC ROUTE FOR NEUTRAL MORPHOLINO OLIGONUCLEOTIDES WITH PHOSPHORYL GUANIDINIUM (PG) BACKBONE | Final Rejection | Bio-Synthesis, Inc. |
| 17616966 | METHODS OF REJUVENATING AGED TISSUE BY INHIBITING 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE (15-PGDH) | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18259368 | DISACCHARIDES FOR TREATING BONE DISEASES | Non-Final OA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE |
| 18031832 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | Non-Final OA | The Regents of the University of Michigan |
| 17633254 | HYBRID AMIDE DERIVATIVES OF AMPHOTERICIN B | Final Rejection | The Board of Trustees of the University of Illinois |
| 17291588 | METHODS FOR CONSOLIDATING ANTIBIOTIC-ELUTING POLYMERIC MATERIALS | Final Rejection | THE GENERAL HOSPITAL CORPORATION |
| 17258868 | POLYMER COMPOUND AND PROMOTER FOR INTRODUCING COMPOUND INTO CELLS USING SAME | Non-Final OA | ADEKA CORPORATION |
| 18269213 | MOLECULE FOR INDUCING SPONTANEOUS CALCIFICATION OF TUMOR CELLS AND USE THEREOF | Non-Final OA | ZHEJIANG UNIVERSITY |
| 17265387 | METHODS FOR REDUCING ABNORMAL SCAR FORMATION | Non-Final OA | CORNELL UNIVERSITY |
| 18263124 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | Non-Final OA | Daiichi Sankyo Company, Limited |
| 18252838 | COMPLEX OF BETA-GLUCAN AND NUCLEIC ACID HAVING CONTROLLED PARTICLE SIZE | Final Rejection | DAIICHI SANKYO COMPANY, LIMITED |
| 18742011 | HYDROPHOBIC INTERACTION CHROMATOGRAPHY FOR PURIFICATION OF OLIGONUCLEOTIDES | Final Rejection | Biogen MA Inc. |
| 18121090 | OPTIMIZED METHOD FOR DECONTAMINATING PRODUCTION OF GLUCOSE POLYMERS AND GLUCOSE POLYMER HYDROLYZATES | Non-Final OA | ROQUETTE FRERES |
| 18693693 | Triple Drug Combination (Metformin, Simvastatin, Digoxin) for Targeted Treatment of Colorectal Cancer | Final Rejection | Whispergenics. Inc. |
| 17905913 | COMPOSITIONS AND METHODS FOR AGE RELATED EYE DISEASES COMPRISING HIGH CONCENTRATIONS OF VITAMINS | Final Rejection | BAUSCH + LOMB IRELAND LIMITED |
| 18349517 | SOY ISOFLAVONES FOR ASTHMA PREVENTION | Final Rejection | Ann & Robert H. Lurie Children's Hospital of Chicago |
| 18000962 | RNA PURIFICATION METHOD | Non-Final OA | ETHERNA IMMUNOTHERAPIES NV |
| 18288057 | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND | Non-Final OA | NIPPON SHINYAKU CO., LTD. |
| 18266331 | PHARMACEUTICAL APPLICATION OF FUSED RING PHENOLIC COMPOUNDS | Non-Final OA | RISEN (SUZHOU) PHARMA TECH CO. LTD. |
| 18281352 | N-(2-AMINOETHYL)MORPHOLINE-BASED RNA ANALOGS, METHOD FOR THE PREPARATION AND USE THEREOF | Non-Final OA | Uniwersytet Warszawski |
| 17597910 | USE OF E-SELECTIN ANTAGONISTS TO ENHANCE THE SURVIVAL OF RECONSTITUTED, BONE MARROW-DEPLETED HOSTS | Non-Final OA | GLYCOMIMETICS, INC. |
| 18365835 | METHODS FOR THE TREATMENT OF FAMILIAL HETEROZYGOUS AND HOMOZYGOUS HYPERCHOLESTEROLEMIA WITH CYCLODEXTRINS | Non-Final OA | Beren Therapeutics P.B.C. |
| 18256080 | Prebiotic Composition for Butyric Acid Bacteria | Non-Final OA | MORINAGA MILK INDUSTRY CO., LTD. |
| 18088285 | NOVEL COMPOUNDS WITH DUAL INHIBITION ACTIVITY AGAINST SARS-COV-2 CRITICAL ENZYMES RDRP, MPRO AND HUMAN TMPRSS2 | Final Rejection | University of Sharjah |
| 18265111 | FUNCTIONALIZED AND CROSSLINKED POLYMERS | Final Rejection | PMIDG, LLC |
| 18253283 | PHARMACEUTICAL COMPOSITION FOR USE IN THE PREVENTION OR TREATMENT OF A CONDITION ASSOCIATED WITH A REDUCTION IN THE NUMBER OF LACTOBACILLI IN THE VAGINA | Non-Final OA | King’s College London |
| 17421111 | OLIGONUCLEOTIDE DEPOSITION ONTO POLYPROPYLENE SUBSTRATES | Final Rejection | QUANTUMDX GROUP LIMITED |
| 18170512 | A 5'-CAP ANALOG MODIFIED mRNA | Non-Final OA | Nanjing GeneLeap Biotechnology Co., Ltd. |
| 18070435 | PARAXANTHINE-BASED COMPOSITIONS FOR ENHANCING MUSCLE FUNCTION, NITRIC OXIDE SIGNALING, AND/OR MUSCLE GLYCOGEN LEVELS | Final Rejection | Ingenious Ingredients, LP |
| 17856542 | METHOD FOR NEUTRALIZING STOMACH ACID USING ALGINATE, POLYLYSINE, AND SEED PRESERVATIVES | Non-Final OA | REFLUX GOURMET LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy